XR Securities’s Aurinia Pharmaceuticals AUPH Stock Holding History

XR Securities’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,100	Closed	-$111K	–	378
2023 Q1	$111K	Sell	10,100 -100	-1%	-$881	﹤0.01%	389
2022 Q4	$44.1K	Buy	+10,200	New	+$59.2K	﹤0.01%	492

Other funds holding AUPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

XR Securities's AUPH Position: Q2 2023 in Review

XR Securities sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2023, closing a stake of 12,000 shares — an estimated $132K sold.

XR Securities first reported a position in AUPH in Q4 2022 and held it in 2 quarters. The position peaked at $132K in Q1 2023. 200 funds tracked by Wall St. Rank hold AUPH as of Q2 2023.

XR Securities reported no remaining Aurinia Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
XR Securities sold 12,000 Aurinia Pharmaceuticals shares in Q2 2023, an estimated $132K.
XR Securities first reported a position in Aurinia Pharmaceuticals in Q4 2022 and held it in 2 quarters.
XR Securities's Aurinia Pharmaceuticals position peaked at $132K in Q1 2023.
200 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2023.

Based on XR Securities's 13F filing for Q2 2023, filed 8 Aug 2023.